Data Reveals Cost Effectiveness Of HPV Vaccine
New modelling research will show that up to 70% of cases of cervical cancer and 95% of cases of genital warts in men and women could be prevented by the introduction of human papilloma virus (HPV) vaccination into the UK 's national immunisation programme. This is in addition to the cancer cases already prevented by the NHS cervical screening programme.
HPA researchers have been examining how long vaccine protection may last. They have considered the cost of the vaccine, the cost to the health service of treating people with conditions caused by HPV and the effect that cervical cancer and genital warts had on quality of life. The research which will be presented today suggests that the HPV vaccination is likely to be an effective use of health care resources if the vaccine protected girls against the virus for at least 20 years.
There is considerable uncertainty in many key factors used in this modelling work, and the team notes that careful monitoring of the effectiveness of HPV vaccination will need to be in place to assess the true impact of a programme in the UK.
The work will be used to inform recommendations to the Department of Health about national immunisation policy, subject to its being approved by a panel of public health experts.
Mark Jit, who led the research for the Health Protection Agency, said